Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 5th edition, 486 pages

Free download

  Lung Cancer

  Free Subscription


1 Ann Oncol
2 Ann Thorac Surg
1 Arch Pathol Lab Med
1 BMC Cancer
1 Cancer Cell
8 Chest
1 Clin Cancer Res
1 Clin Lung Cancer
2 Eur J Cancer
1 Eur J Cardiothorac Surg
1 Int J Cancer
1 J Nucl Med
1 J Thorac Oncol
1 Oncogene

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Oncol

  1. TAN L, Solomon BJ
    Defining Resistance Mechanisms to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer (editorial re: Lin et al.).
    Ann Oncol. 2020 Oct 9. pii: S0923-7534(20)42493.

    Ann Thorac Surg

  2. DARLING GE, Tammemagi MC, Schmidt H, Buchanan DN, et al
    Organized Lung Cancer Screening Pilot: Informing a Province-wide Program in Ontario, Canada.
    Ann Thorac Surg. 2020 Oct 8. pii: S0003-4975(20)31623.
    PubMed         Abstract available

  3. LECLERE JB, Fournel L, Etienne H, Al Zreibi C, et al
    Maintaining surgical treatment of non-small cell lung cancer during the COVID-19 pandemic in Paris.
    Ann Thorac Surg. 2020 Oct 7. pii: S0003-4975(20)31631.
    PubMed         Abstract available

    Arch Pathol Lab Med

  4. STAAF J, Tran L, Soderlund L, Nodin B, et al
    Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers.
    Arch Pathol Lab Med. 2020;144:1075-1085.
    PubMed         Abstract available

    BMC Cancer

  5. LENG D, Yi J, Xiang M, Zhao H, et al
    Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling.
    BMC Cancer. 2020;20:986.
    PubMed         Abstract available

    Cancer Cell

  6. LIANG W, Liu J, He J
    Driving the Improvement of Lung Cancer Prognosis.
    Cancer Cell. 2020;38:449-451.
    PubMed         Abstract available


  7. VERDIAL FC, Berfield KS, Wood DE, Mulligan MS, et al
    Safety and Costs of Endobronchial Ultrasound-Guided Nodal Aspiration and Mediastinoscopy.
    Chest. 2020;157:686-693.
    PubMed         Abstract available

  8. WAHIDI MM, Herth FJF, Chen A, Cheng G, et al
    State of the Art: Interventional Pulmonology.
    Chest. 2020;157:724-736.
    PubMed         Abstract available

  9. GRUDEN JF, Naidich DP, Machnicki SC, Cohen SL, et al
    An Algorithmic Approach to the Interpretation of Diffuse Lung Disease on Chest CT Imaging: A Theory of Almost Everything.
    Chest. 2020;157:612-635.
    PubMed         Abstract available

  10. GIBIER JB, Colombat M, Grardel N, de Charette M, et al
    An 80-Year-Old Woman With a Solitary Pulmonary Nodule.
    Chest. 2020;157:e85-e89.
    PubMed         Abstract available

  11. YANG H, Hall SRR, Yao F
    The Value of PD-L1 Expression in Metastatic Lymph Nodes of Advanced Non-Small Cell Lung Cancer.
    Chest. 2020;158:1785-1787.

    Lung Cancer Screening: No Shared Decision-making When Overlooking Carl Rogers.
    Chest. 2020;158:1795-1796.

  13. Correction to Text in: Lung Cancer Screening Uptake in the United States.
    Chest. 2020;158:1797.

  14. KUNITOMO Y, Young G, Datta R, Korn LL, et al
    A 62-Year-Old Woman With Lung Cancer, Ulcerating Rash, and Rapidly Progressive Hypoxemia.
    Chest. 2020;158:e191-e196.
    PubMed         Abstract available

    Clin Cancer Res

  15. YU HA, Paz-Ares LG, Yang JC, Lee KH, et al
    Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Oct 12. pii: 1078-0432.CCR-20-1690.
    PubMed         Abstract available

    Clin Lung Cancer

  16. CUSHMAN TR, Jones B, Akhavan D, Rusthoven CG, et al
    The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30265.
    PubMed         Abstract available

    Eur J Cancer

  17. TAI YH, Wu HL, Mandell MS, Lin SP, et al
    The association of non-small cell lung cancer recurrence with allogenic blood transfusion after surgical resection: A propensity score analysis of 1,803 patients.
    Eur J Cancer. 2020;140:45-54.
    PubMed         Abstract available

  18. SHIRASAWA M, Yoshida T, Matsumoto Y, Shinno Y, et al
    Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
    Eur J Cancer. 2020;140:28-36.
    PubMed         Abstract available

    Eur J Cardiothorac Surg

  19. HANDA Y, Tsutani Y, Okada M
    Reply to Li and Che.
    Eur J Cardiothorac Surg. 2020;57:614-615.

    Int J Cancer

  20. WAH W, Stirling RG, Ahern S, Earnest A, et al
    Influence of Timeliness and Receipt of First Treatment on Geographic Variation in Non-small Cell Lung Cancer Mortality.
    Int J Cancer. 2020 Oct 12. doi: 10.1002/ijc.33343.
    PubMed         Abstract available

    J Nucl Med

  21. CHRISTENSEN TN, Langer SW, Persson GF, Larsen KR, et al
    (18)F-FLT-PET/CT adds value to (18)F-FDG-PET/CT for diagnosing relapse after definitive radiotherapy in patients with lung cancer. Results of a prospective clinical trial.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.247742. doi: 10.2967/jnumed.120.247742.
    PubMed         Abstract available

    J Thorac Oncol

  22. STINCHCOMBE TE, Doebele RC, Wang X, Gerber DE, et al
    Brief report: Preliminary clinical and molecular analysis results from a single arm phase 2 trial of brigatinib in patients with disease progression after next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in advanced ALK + no
    J Thorac Oncol. 2020 Oct 8. pii: S1556-0864(20)30764.
    PubMed         Abstract available


  23. SHEN H, Wang GC, Li X, Ge X, et al
    S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Oncogene. 2020 Oct 9. pii: 10.1038/s41388-020-01497.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.